Updated Clinical Data of Zocilurtatug Pelitecan (Zoci) in Previously Treated Extrapulmonary Neuroendocrine Carcinomas Presented
“We are increasingly excited about the potential of zoci to provide an important new targeted therapeutic option for patients with multiple cancer types that commonly express DLL3, including epNECs,” said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab. “We are pleased that results from this larger dataset, with longer follow-up, are consistent with the earlier data we shared at AACR. A confirmed objective response rate of 40 percent, including response in multiple epNEC subtypes, with anti-tumor activity observed over time and a treatment related discontinuation rate of less than one percent, are encouraging signals for patients who have few treatment options following platinum-based chemotherapy. We are pursuing an accelerated approval pathway for zoci in previously treated epNECs and will continue to advance our clinical programs for this disease with urgency.”
Share:
More News
“We are pleased with the outcome of our End-of-Phase 1 meeting with FDA and are confident in our development strategy for BH-30643 in EGFR C797S-positive NSCLC. Our planned Phase 2 trial, designed with registrational intent, builds on the encouraging clinical activity observed in SOLARA, where BH-30643 has demonstrated promising anti-tumor
Jai Rautela, Ph.D., MBA, Chief Executive Officer, Audax Biosciences, “Astellas shares our pioneering spirit in immuno-oncology making them an ideal partner for highly differentiated programs such as DAX-044. This partnership will expedite the planned phase 1 clinical evaluation of DAX-044 for the benefit of patients with various types of solid
“FDA clearance of the IND for KT-300, a potential first-in-class TRIM7 inhibitor, is an important milestone for Kayak and brings our novel approach to RAS-driven cancers into the clinic,” said Josiah Hornblower, CEO of Kayak Therapeutics. “TRIM7 sits at a critical downstream node of the RTK–RAS signaling cascade, and its
“Saros is advancing a next-generation immunotherapy platform designed to help the immune system recognize and attack cancers that do not respond well to today’s checkpoint inhibitors,” said Saros CEO Matt Britz. “Our formulation is designed to enhance immune activation, protect the drug in circulation, improve delivery into relevant immune cells